Zai Lab’s deep As well as its regional footprint, make it an ideal partner as we work to bring Pove to patients in China and beyond,” said Reshma Kewalramani, Ph.D., CEO and President of Vertex. “We are very pleas to be working with Zai Lab, which moldova email list 100000 contact leads will enable us to accelerate the delivery of this potentially bestinclass therapy to the patients who are waiting.”
Dr. Ying Du, Founder, Chairman and CEO of Zai Lab, said: “Pove is an important expansion of our existing product portfolio and will continue to strengthen our leading position in immunology in China. We are committ to bringing innovative therapies to patients in ne and are pleas to work with Vertex to make Pove available to patients in China and beyond.”
About Povetacicept
Povetacicept is a recombinant fusion protein therapy that is a dual antagonist of BAFF (Bcell activating factor) and APRIL (proliferationinducing ligand), several cytokines that play key roles in the pathogenesis of multiple autoimmune diseases through their roles in the activation, differentiation and/or survival of B cells, T cells and innate digital marketing trends in 2023 immune cells. Bas on an engineer TACI (transmembrane activator and calmodulin ligand interactor) domain, povetacicept has higher binding affinity and greater potency than other BAFF and/or APRIL inhibitors in preclinical studies and has demonstrat potential bestinclass efficacy in clinical studies in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also being develop for the treatment of a variety of serious Bcellmiat diseases, including other autoimmune kidney diseases and autoimmune cytopenias.
About IgA Nephropathy
IgA nephropathy is a severe, progressive, lifethreatening Bcellmiat chronic kidney disease and the most common cause of primary (idiopathic) glomerulonephritis. It is estimat that there are approximately 3 to 5 million IgA nephropathy trust review patients in China15. IgA nephropathy is caus by the deposition of circulating immune complexes of immunoglobulin (Ig) and galactoseficient IgA1 (GdIgA1) in the glomerular mesangium, leading to renal damage and fibrosis. A large proportion of patients with IgA nephropathy will develop endstage renal disease. There are currently no approv therapies that specifically target the cause of IgA nephropathy Zai Lab’s deep.
